Hims & Hers Health is adding longtime Novo Nordisk executive Kåre Schultz to its board of directors after its move into the booming market for weight-loss drugs trib.al/oWgtv1Q

Hims & Hers has a 'long future' in selling off-brand Ozempic, former Novo Nordisk executive says qz.com/hims-hers-novo…

Kåre Schultz was the COO of Novo Nordisk, a $500B pharma company, from 2002-2015. Thereafter he served as CEO of Lundbeck and Teva Pharmaceuticals. He was just appointed to $HIMS board of directors. He just said that this is the first company to truly break down barriers and

This piece from Arthur Allen is a must-read for anyone looking to understand how compounding as a practice is critical to ensuring access to healthcare for millions. The current state of access around weight loss drugs isn’t serving everyone who needs them – and rigorous,

I caught up with Hope King today to talk $HIMS growth and where we're headed, including how we're expanding. Our long history in compounding is the foundation of our investments and our ability to expand the scale of our impact across our platform. There is no one-size-fits-all

Weight-loss drugs are providing a spark for hims, but there’s a lot more investors should be paying attention to, says CEO andrewdudum. He speaks w/ Hope King about why obesity drugs aren’t make-or-break for $HIMS, the safety process for compounded drugs, & more.

An estimated 100 million people in the US struggle with weight-related challenges and are struggling to access the GLP-1 medications they need, whether because of limited supply, outrageous cost, or an approach to dosing that isn’t tailored for the best individual outcome. Some

To quote Bernie Sanders .. Let's be clear - even with this modest price reduction for Zepbound, millions of Americans will still be unable to afford the drugs they desperately need. bloomberg.com/news/newslette…

In the US, even having health insurance doesn’t mean access to the care you need. As more individuals qualify for these costly medications, plans are more likely to decline to cover them because healthcare incentives in the US are based on cost, not outcomes. This backwards way